Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC. Recently, immunotherapy developed rapidly. The purpose of this study was to observe the efficacy and safety of cardonilizumab combined with chemoradiotherapy in the treatment of locally advanced ESCC.

Trial Details

NCT ID

NCT06421376

Phase

PHASE2

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Esophageal Cancer

Interventions

Cardonilizumab
Chemoradiotherapy ±immunotherapy
Radical surgery

Locations (sample)

Anyang, Henan, China|36.096,114.38278
Xinxiang, Henan, China|35.19033,113.80151
Beijing, China|39.9075,116.39723

Key Eligibility Criteria

18-80 years old；
Eligible patients were histologically confirmed esophageal squamous cell carcinoma;
Eligible patients were proven locally advanced ESCC (cT1-2N1-3M0-1, cT3/T4N0-3M0-1, M1 was limited to supraclavicular lymph node metastasis）diagnos…
ECOG PS score: 0\~1；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →